

11 March 2026

To,
BSE Limited
 Phiroze Jeejeebhoy Towers,
 Dalal Street,
 Mumbai - 400 001

Scrip Code: 524669

Dear Sir:

To,
National Stock Exchange of India Limited
 Exchange Plaza,
 Bandra - Kurla Complex,
 Bandra (E), Mumbai - 400 051

Symbol: HESTERBIO

Subject: Outcome of Board Meeting and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Divestment of Equity stake in Texas Lifesciences Private Limited, Subsidiary

Pursuant to Regulation 30, read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), including any amendments thereto, we hereby inform you that the Board of Directors at the meeting held on 11 March 2026, and on the recommendations of the Audit Committee of the Board, considered and approved the Divestment of 43.81% equity shareholding out of total 54.81% in its subsidiary, Texas Lifesciences Private Limited ("TLPL"), by way of transfer/sale of shares to the existing promoter shareholders of the TLPL. TLPL is not material subsidiary of the Company. TLPL will ceased to be the subsidiary of the Company upon completion share transfer transaction as above.

The Board Meeting commenced at 10:46 a.m. (IST) and concluded at 11:05 a.m. (IST).

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 are given as under:

Name and shareholding of the Subsidiary	Texas Lifesciences Private Limited ("TLPL") Current Shareholding: 54.81%
The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	FY 2024-25 Turnover: INR 285.89 million Net Worth: INR 134.17 million More than 97% of sale to the HBL, which has been eliminated while preparing the consolidated financial statements of the Hester Biosciences.
Date on which the agreement for sale has been entered into;	5 March 2026
The expected date of completion of sale/disposal;	The transfer of shares shall be completed within a period of 3 (three) months from the date of this Agreement.
Consideration received from such sale/disposal;	Total aggregate value of INR 92 million subject to terms and conditions of agreement.

<p>Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;</p>	<p>The 43.81% shareholding of Hester will be transferred to Ticop Life Private Limited, a Company affiliated to the existing promoter shareholders of TLPL. Hester will continue to do business with TLPL and maintain an 11% equity stake/investment in the company.</p>
<p>Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";</p>	<p>No. The transaction pertains to the sale of shares between Ticop Life Private Limited, a Company affiliated to the existing promoter shareholders of the subsidiary, and Hester Biosciences, and the parties to the transaction are not related parties.</p>
<p>Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.</p>	<p>Not Applicable</p>
<p>Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.</p>	<p>Not Applicable</p>

You are requested to take the above information on your record.

**Sincerely,
For Hester Biosciences Limited**

**Vinod Mali
Company Secretary & Compliance Officer**